Q9996 Ustekinumab Injection Reimbursement

HCPCS Level II code Q9996 designates the subcutaneous injection of ustekinumab-ttwe (Pyzchiva), dosed as 1 mg per unit. As a HCPCS Level II product code for a biologic therapeutic, it matters nationally for billing, supply management, and coverage determinations tied to specialty medications administered in outpatient and ambulatory settings. The code aids payers and providers in identifying the specific biosimilar/therapeutic formulation for claims and utilization tracking.

Key payers included in standard coverage analyses are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for ustekinumab-class therapies, typical sites of service for subcutaneous administration, and what the HCPCS code identifies on claims. The publication also outlines common modifiers and administrative considerations associated with HCPCS Level II product codes, and flags where input data was not provided for associated taxonomies, ICD-10 diagnoses, or related codes.

This national-level summary is intended to inform revenue cycle, pharmacy, and clinical teams about the billing identity of Pyzchiva injections, how the code is used on service lines, and the payer landscape relevant to coverage and claim adjudication.

Billing Code Overview

HCPCS Level II code Q9996 describes the injection of ustekinumab-ttwe (Pyzchiva), subcutaneous, 1 mg. This code represents a biologic therapeutic administered via subcutaneous injection for indications aligned with ustekinumab products.

Service type: Subcutaneous biologic injection
Typical site of service: Ambulatory clinic, outpatient infusion/administration center, physician office, or other outpatient settings where subcutaneous biologic injections are administered

Clinical Context

A 42-year-old patient with moderate-to-severe plaque psoriasis presents to an outpatient infusion or specialty injection clinic for administration of maintenance subcutaneous biologic therapy. The patient has previously completed induction dosing and is scheduled for a maintenance dose of ustekinumab-ttwe (Pyzchiva) delivered as a subcutaneous injection. Typical workflow: verification of identity and insurance benefit coverage, review of allergies and current medications, brief focused skin and systemic assessment, documentation of weight and recent response to therapy, preparation of the prefilled syringe, administration of the subcutaneous injection by an RN or trained medical assistant in the clinic or ambulatory specialty infusion area, observation for immediate adverse reaction (15–30 minutes depending on payer/staffing protocols), documentation of lot number and expiration, and billing using the HCPCS Level II code Q9996 for the medication supplied. Typical site of service is an outpatient specialty clinic, dermatology office, or ambulatory infusion center. Common clinical reasons for use include moderate-to-severe plaque psoriasis and psoriatic arthritis when systemic biologic therapy is indicated.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier (standard)	Use for routine administration when no special circumstances apply.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Dermatology	Most common specialty prescribing and administering ustekinumab for plaque psoriasis.
`207XS0102X`	Allergy & Immunology	Manages biologic therapy for immune-mediated skin and systemic conditions.
`363A00000X`	Infectious Disease / Ambulatory Infusion Specialist (note: infusion nurse taxonomy)	Nurses and infusion specialists administer and monitor biologic injections in ambulatory infusion centers.
`2080P0217X`	Rheumatology	Prescribes and follows patients with psoriatic arthritis receiving biologic therapy.
`173L00000X`	Dermatopathology (supporting role)	Provides diagnostic confirmation when biopsy guidance informs biologic therapy decisions.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L40.0`	Psoriasis vulgaris	Primary indication for ustekinumab therapy in moderate-to-severe plaque psoriasis.
`L40.5`	Arthropathic psoriasis	Indicates psoriatic arthritis where systemic biologic therapy such as ustekinumab may be used.
`L40.8`	Other psoriasis	Includes less common psoriasis subtypes that may be treated with biologic agents when appropriate.
`M07.0`	Distal interphalangeal psoriatic arthropathy	Specific psoriatic arthritis code relevant when joint involvement necessitates biologic therapy.
`M07.3`	Psoriatic arthritis mutilans	Severe psoriatic arthritis subtype where systemic biologic therapy may be indicated.
`L40.9`	Psoriasis, unspecified	Used when psoriasis is documented but subtype is not specified; supports biologic treatment justification.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used to report the professional administration service when a separate administration code is billed alongside the drug HCPCS code `Q9996` depending on payer-specific bundling rules.
`81002`	Urinalysis, non-automated, without microscopy (single)	Performed occasionally for baseline labs or monitoring in systemic therapy workflows; performed before or during treatment visit when clinically indicated.
`36415`	Collection of venous blood by venipuncture	Used to obtain laboratory monitoring specimens (e.g., baseline labs, safety monitoring) associated with initiation or periodic monitoring of biologic therapy.
`99070`	Supplies and materials (except spectacles), non-covered items or services	Used when additional supplies (e.g., special needles, skin antiseptics) are separately billable per payer policy.
`99024`	Postoperative follow-up visit, included in global service	Rarely used; may be referenced for global period reporting when biologic therapy is given in perioperative contexts.

OpenPayer

Summary & Overview

HCPCS Q9996: Ustekinumab-ttwe (Pyzchiva) Injection, Subcutaneous 1 mg